Background {#Sec1}
==========

The worldwide epidemiology of childhood Type 1 diabetes (T1D) was extensively described in the 6th edition of the International Diabetes Federation (IDF) \[[@CR1]\]. Data were retrieved in approximately 45% of the countries \[[@CR1]-[@CR4]\]. In contrast, we are unaware of a similar review on the worldwide epidemiology of adult T1D diabetes, although T1D is known to occur even late in adults \[[@CR5]-[@CR7]\]. A major limitation of the epidemiology of T1D in adults is certainly the difficulty there is to distinguish it from Type 2 diabetes (T2D) requiring insulin treatment or from Latent Autoimmune Diabetes in Adults (LADA), when specific markers of autoimmunity are not searched.

Here, our primary objective was to describe -- through a systematic review of the literature -- the available published information on adult T1D incidence, and the diagnostic criteria used for case definition. A secondary objective was to study how the variations of T1D incidence in adults mirrored those in children.

Methods {#Sec2}
=======

Literature review {#Sec3}
-----------------

A systematic review was conducted according to the PRISMA recommendations to retrieve original papers published in English, French and Spanish up to November 6th, 2014, in peer-reviewed journals reporting the incidence of T1D among individuals aged more than 15 years, in population-based studies (*i.e.* collected in a defined geographic area \[[@CR8]\]) and reporting the diagnostic criteria used to define T1D.

The databases used for the literature search were Medline (PubMed), Google Scholar and Thomson Reuters (Web of Knowledge). The protocol of the search was registered in the International Prospective Register of Systematic Reviews (PROSPERO) and is available on <http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002369> (Registration number: 2012:CRD42012002369). Figure [1](#Fig1){ref-type="fig"} presents the flow diagram of the bibliographic search, Additional file [1](#MOESM1){ref-type="media"} for the full electronic search strategy, and Additional file [2](#MOESM2){ref-type="media"} for the PRISMA checklist.Figure 1**PRISMA Flow diagram bibliographic search strategies.** \* Kumar P, et al. Indian Med Assoc. 2008;106(11):708--711. \*\* The article: Radosevic B, et al. Pediatr Diabetes. 2013;14(4):273--4 gives information from two countries: 1) Bosnia and Herzegovina: Republic of Srpska and 2) Slovenia, Nationwide.

Data collection {#Sec4}
---------------

For each study, the following information was extracted:the identification of the study: authors, title, journal, publication year,the period and country of study. The country was categorized by its World Health Organization (WHO) region and economic level: high-income (HIGH) or low- and middle-income (LMIC) \[[@CR9]\],the geographic coverage of the study: nationwide (when the study was performed in the entire nation) and local (when it was restricted to a given region, city, or a geographically defined population),the diagnostic criteria used to define T1D in adults: detection of autoantibodies against beta-cells (such as: islet cell antibody (ICA), insulin autoantibody (IAA), islet antigen-2 autoantibody (IA-2), anti-glutamic acid decarboxylase antibodies (GAD)), measurement of the fasting C-peptide level \[[@CR7]\], need for permanent insulin therapy, time when the administration of insulin therapy was started, and clinical signals of T1D diabetes such as ketosis, ketonuria and weight loss,the sources of data/registers reporting T1D incidence in the studies, defined according to LaPorte et al. \[[@CR10]\] as: *primary* source of information: a "well-established system of standardized registries for identifying new cases", for example national or regional registers, *secondary* source of information: other different sources of cases "that would provide a check on the degree of ascertainment", for example medical records or hospital discharges, and *tertiary* source of information: a third approach for identifying cases, for example, through surveillance system or death certificates,the reported percentage of completeness/ascertainment between sources of information reporting incidence \[[@CR10]\],the incidence rates reported in the text, tables or graph (expressed as new cases per 100.000 persons/year) by sex and age classes,additional information such as those concerning rural/urban, or ethnic differences.

Data analyses {#Sec5}
-------------

The country distribution of the T1D incidence information and the analysis of the diagnostic criteria used were performed on the entire set of articles retrieved. For the few papers for which the results were presented by ethnic origin, we estimated the mean value of the incidence for the given period in the countries/regions concerned.

Correlation between adult and children T1D incidences {#Sec6}
-----------------------------------------------------

In the geographical correlation analyses between children and adult incidences, we considered for each country the more recent nationwide study published, or if not available, the last published set of local studies retrieved from a given area in the country; in addition, we included all published papers reporting auto-antibodies against beta-cells or C-peptide. To obtain an estimate of the incidence of T1D in children in the countries for which the adult incidence was available, we used the data provided by the same adult paper, when available. The incidence of T1D in children was not available in 9 of these papers included in the geographical correlation analyses. In this case, it was estimated through a separate systematic review focused on the corresponding countries and periods (see Additional file [3](#MOESM3){ref-type="media"}).

Statistics {#Sec7}
----------

Data were extracted from graphs using GraphClick \[[@CR11]\].

The country-to-country co-variation of children and adult incidences was quantified by the Spearman correlation and a linear regression.

The R software (version 3.0.1) was used for statistical and graphic analyses \[[@CR12]\].

Results {#Sec8}
=======

Description of the information obtained from the systematic review on adult T1D {#Sec9}
-------------------------------------------------------------------------------

Seventy articles reporting incidence of T1D in young adults and adults aged over than 15 years concerned one country, and one article concerning two countries were retrieved in this systematic review, resulting in a total of 71 studies covering 35 countries (Table [1](#Tab1){ref-type="table"}). Twenty-four of the 71 studies were nationwide; 43 papers provided information on the T1D incidence in the age class 15--29 years, 26 in the age class 30--59 years, and 6 in the persons aged \>60 years.Table 1**Systematic review of T1D in adults, diagnostic criteria and sources of informationStudy informationT1D diagnosis criteria in adults and young adultsSource of information and validation of ascertainment between sourcesCountry, area reported in the articleFirst author, publication yearRefAge rangePeriodDetect. AA/C-PeptideNeed of insulin therapyAdministration insulin therapyClinical impressionKetosis/ ketonuriaWeight lossPrimarySecondaryTertiary% of ascertainmentAfrican Region, LMIC**Mauritius: NWTuomileht J., 1993^†^\[[@CR13]\]0-191986-1990NoYesFrom diagnosisYesNANAMedical reportsMedical statisticsNA95.0United Republic of Tanzania: Dar es SalaamSwai A. B., 1993^†^\[[@CR14]\]0-191982-1991NoYesFrom diagnosisYesNANAMedical reportsHospital recordsNANA**Eastern Mediterranean Region, LMIC**Iran (Islamic Republic of): Fars**Pishdad G. R., 2005** ^**†**^\[[@CR15]\]0-291990-1994**Yes (a)**YesFrom diagnosisYesYesYesMedical reports from endocrinologistsMedical recordsNA100Libyan Arab Jamahiriya: BenghaziKadiki O. A., 1996^†^\[[@CR16]\]0-341981-1990NoYesFrom diagnosisNAYesNANational Diabetes ProgramHospital registersNA95.0Tunisia: Beja, Monastir, GafsaBen Khalifa F., 1998^†^\[[@CR17]\]0-191990-1994NoYesFrom diagnosisYesNANAHospital recordsSchool health centersNA96.0**European Region, LMIC**Croatia: ZagrebRoglic G., 1995^†^\[[@CR18]\]0- \> 551988-1992NoYesWithin 1 week of diagnosisYesYesNANational Diabetes ProgramDeath certificatesDiabetes association96.2Estonia: NWKalits I., 1990^†^\[[@CR19]\]0- \> 501988-1988NoYesFrom diagnosisYesYesYesNANANANALithuania: NWOstrauskas R., 2011^†^\[[@CR20]\]15-341991-2008NoYesWithin 2 weeks of diagnosisYesYesYesNational Diabetes ProgramRegional endocrinologistNotes of patient insurance86.8Lithuania: NWPundziute-Lycka A., 2003\[[@CR21]\]0-391991-2000NoYesWithin 2 weeks of diagnosisYesYesNANational Diabetes ProgramPediatrician and endocrinologist reportsDeath certificates91.2Lithuania: NWOstrauskas R., 2000\[[@CR22]\]15-391991-1997NoYesWithin 2 weeks of diagnosisYesYesNANational Diabetes ProgramPediatrician and endocrinologist reportsDeath certificates91.2Poland: BialystokKretowski A., 2001^†^\[[@CR23]\]0-291994-1998NoYesFrom diagnosisYesYesYesPediatric and Internal medicine recordsHospital discharge registersNA98.5Poland: Province of RzeszowSobel-Maruniak A., 2006^†^\[[@CR24]\]0-291980-1999NoYesFrom diagnosisYesNANAPediatric and Internal medicine recordsOthers health care registersNA99.0Poland: Province of RzeszowGrzywa M. A., 1995\[[@CR25]\]0-291980-1992NoYesFrom diagnosisYesNANAPediatric and Internal medicine recordsOthers health care registersNA99.0Poland: WarsawWysock M. J., 1992^†^\[[@CR26]\]0-291983-1988NoYesFrom diagnosisYesNANAMedical records from diabetic clinicsGeneral practitioners and diabetologist registersDeath certificatesNARomania: BucharestIonescu-Tirgoviste C., 1994^†^\[[@CR27]\]0- ≥ 851981-1991NoYesFrom diagnosisYesYesNABucharest Diabetes RegistryNANANASlovakia: NWKyvik K O, 2004^†^\[[@CR28]\]15-291996-1997NoYesFrom diagnosisYesNANAPediatrician and endocrinologist reportsOther health care registersNA80.0**European Region, HIGH**Austria: UpperRami B., 2001^†^\[[@CR29]\]0-291994-1996NoYesFrom diagnosisYesNANAPediatricians and endocrinologists reportsAustrian Diabetes AssociationNA87.0Belgium: Antwerp**Weets I**., **2007** ^**†**^\[[@CR30]\]0-391989-2003**Yes**YesFrom diagnosisYesNANAPediatricians and endocrinologists reportsGeneral practitioners and diabetes nurses reportsDiabetes associations and self-reporting97.0Belgium: Antwerp**Weets I., 2002** ^**†**^\[[@CR31]\]0-391989-2000**Yes**YesFrom diagnosisNANANAPediatrician and endocrinologist reportsGeneral practitioner and diabetes nurse reportsDiabetes associations and self-reporting93Belgium: Antwerp**Vandewalle C., 1997** ^**†**^\[[@CR32]\]0-391989-1995**Yes**YesFrom diagnosisYesYesYesPediatrician and endocrinologist reportsGeneral practitioner and diabetes nurse reportsDiabetes associations and self-reporting85Bosnia and Herzegovina: Republic of SrpskaRadosevic B., 2013^†^\[[@CR33]\]0-181998-2010NoYesFrom diagnosisYesNANAHospital recordsInsulin prescription registersNA100Denmark: Copenhagen and Frederiksborg**Molbak A. G**., **1994** ^**†**^\[[@CR34]\]30-951973-1977**Yes (b)**YesFrom diagnosisYesYesYesHospital dischargesGeneral practitioners and diabetologist registers and death certificatesMissing coding of T1D diagnosis in hospital admissions99.0Finland: NW**Lammi N**., **2007** ^**†**^\[[@CR35]\]15-391992-1996**Yes**YesFrom diagnosisYesNANANational Diabetes ProgramHospital discharge registersDrug reimbursement registers88.0France: Aquitaine, Lorraine, Basse Normandie, Haute NormandieCharkaluk M. L, 2002^†^\[[@CR36]\]0-191988-1997NoYesNone declaredNANANAProspective registersFrench Social Security registersNA96.0France: Aquitaine, Lorraine, Basse Normandie, Haute NormandieLevy-Marchal, C., 1998\[[@CR37]\]0-191988-1995NoYesNone declaredNANANAProspective registersFrench Social Security registersNA96.0Israel: NWBlumenfeld O., 2014^†^\[[@CR38]\]0-171997-2010NoYesFrom diagnosisYesNANAIsrael juvenile diabetes registerIsrael Center for Disease ControlNANAIsrael: NWSella T., 2011\[[@CR39]\]0-172000-2008NoYesNone declaredYesNANAIsrael juvenile diabetes registerIsrael Center for Disease ControlNANAIsrael: NWKoton S., 2007\[[@CR40]\]0-171997-2003NoYesFrom diagnosisYesNANAIsrael juvenile diabetes registerNANANAItaly: LombardieGarancini, P., 1991†\[[@CR41]\]0-341981-1982NoYesNone declaredNANANAHospital discharge recordsHospital admission recordsNA85.7Italy: PaviaTenconi M. T., 1995^†^\[[@CR42]\]0-291988-1992NoYesFrom diagnosisYesNANAHospital recordsDrug registersNA100Italy: SardiniaMuntoni S, 1992^†^\[[@CR43]\]0-291989-1990NoYesFrom diagnosisYesNANAHospital recordsDiabetes associationNA92.8Italy: Sardinia (Oristano)Frongia O., 1997^†^\[[@CR44]\]0-291993-1996NoYesFrom diagnosisYesNANAHospital recordsDrug registersNA100Italy: Turin**Bruno G**., **2009** ^**†**^\[[@CR45]\]15-292000-2004**Yes**YesWithin 6 months of diagnosisNANANAHospital recordsDrug registersNANAItaly: Turin**Bruno G**., **2005** ^**†**^\[[@CR46]\]30-491999-2001**Yes**YesWithin 6 months of diagnosisNAYesNADiabetes clinicsDrug registersNA99.0Italy: TurinBruno G., 1993\[[@CR47]\]0-291984-1988NoYesFrom diagnosisNAYesNADiabetic clinics recordsHospital discharge recordsNA97.0Luxembourg: NWDe Beaufort C. E., 1988^†^\[[@CR48]\]0-191977-1986NoYesNone declaredNANANAPediatric and Internal medicine recordsDutch Diabetes AssociationNA100Malta: NWSchranz A. G., 1989^†^\[[@CR49]\]0-241980-1987NoYesWithin 3 moths of diagnosisYesYesYesMedical reportsDiabetic clinic recordsNANANetherlands: NWRuwaard D., 1994^†^\[[@CR50]\]0-191988-1990NoYesNone declaredNANANAPediatric and Internal medicine recordsNANA81.0Norway: NWJoner G., 1991^†^\[[@CR51]\]15-291978-1982NoYesFrom diagnosisNANANAPediatricians and endocrinologists reportsHospital recordsNA90.0Slovenia: NWRadosevic B., 2013^†^\[[@CR33]\]0-181998-2010NoYesFrom diagnosisYesNANASlovenian National Registry of Childhood diabetesInsulin prescription registersNA100Spain: BadajozMorales-Perez F. M., 2000^†^\[[@CR52]\]0-291992-1996NoYesFrom diagnosisYesYesNAPediatricians and endocrinologists reportsDiabetic clinic recordsNA95.0Spain: Canarias IslandsCarrillo Dominguez, A., 2000^†^\[[@CR53]\]0-301995-1996NoYesNone declaredYesNAYesHospital records and Endocrinologist reportsDiabetes association reports and sales on blood glucose monitorsNA90.1Spain: Catalonia**Abellana R**., **2009** ^**†**^\[[@CR54]\]0-291989-1998**Yes (c)**YesFrom diagnosisYesYesNACatalan Registry of Type 1 DiabetesSummer camps, associations, and prescription dataNA90.0Spain: CataloniaGoday A., 1992\[[@CR55]\]0-291987-1990NoYesFrom diagnosisYesNANACatalan Registry of Type 1 DiabetesSummer camps, patient associations, and prescription dataNA90.1Spain: Navarra**Forga L**., **2014** ^**†**^\[[@CR56]\]0- \> 452009-2012**Yes**YesWithin 6 months of diagnosisYesYesNAHospital recordsElectronic medical records, diabetes associationsNA98.4Spain: Navarra**Forga L**., **2013** ^**†**^\[[@CR57]\]0-792009-2011**Yes**YesWithin 6 months of diagnosisYesYesNAHospital recordsElectronic medical records, diabetes associationsNA98.4Sweden: NWDahlquist G. G., 2011^†^\[[@CR58]\]0-341983-2007NoYesFrom diagnosisYesYesYesNational Diabetes ProgramPediatricians and endocrinologist reportsNA96.0Sweden: NWÖstman J., 2008\[[@CR59]\]15-341983-2002NoYesFrom diagnosisYesNANANational Diabetes ProgramPediatrician and endocrinologist reportsComputer-based patient administrative register82Sweden: NWPundziute-Lycka A., 2002\[[@CR60]\]0-341983-1998NoYesFrom diagnosisYesYesYesNational Diabetes ProgramPediatrician and endocrinologist reportsComputer-based patient administrative register91.2Sweden: NWNyström L., 1992\[[@CR61]\]0-341983-1987NoYesNone declaredNANANANational Diabetes ProgramHospital admission and discharge registersNA89Sweden: NWBlohme G., 1992\[[@CR62]\]15-341983-1987NoYesFrom diagnosisYesYesYesNational Diabetes ProgramHospital admission and discharge registersNANASweden: Kronoberg**Thunander M**., **2008** ^**†**^\[[@CR63]\]0-1001998-2001**Yes**YesWithin 4 weeks of diagnosisYesYesNAOpportunistic screening of all adult patients in contact with the medical care systemDepartments of ophthalmologyNA98.0United Kingdom: NWImkampe A. K., 2011^†^\[[@CR64]\]0-341991-2008NoYesWithin 3 moths of diagnosisYesNANANational Diabetes ProgramPediatricians and endocrinologist reportsNANAUnited Kingdom: Oxford regionBingley P. J., 1989\[[@CR65]\]0-211985-1986NoYesFrom diagnosisYesNANAMedical reports from general practioners and pediatriciansRegional hospital recordsNA95.0**Region of the Americas, LMIC**Barbados: NWJordan O. W., 1994^†^\[[@CR66]\]0-291982-1991NoYesFrom diagnosisYesNANAHospital recordsOthers health care registersNA94.0**Region of the Americas, HIGH**Canada: QuebecLegault L., 2006^†^\[[@CR67]\]0-182000NoYesNone declaredNANANADepartmental program: Régie des Rentes du Québec programNANANAUnited States of America: Alabama (Jefferson County)Wagenknecht L. E., 1991^†^\[[@CR68]\]0-191979-1988NoYesNone declaredNANANAHospital recordsSummer camps, patient associations, and prescription dataNANAUnited States of America: Alabama (Jefferson County)Wagenknecht L. E.,1989\[[@CR69]\]0-191979-1985NoYesFrom diagnosisYesNANAHospital recordsAssociation registersNA95.0United States of America: ColoradoVehik K., 2007^†^\[[@CR70]\]0-172000-2004NoYesWithin 2 weeks of diagnosisYesNANAPediatricians and endocrinologists reportsOther health care registersThe SEARCH Study96.5United States of America: ColoradoKostraba J. N., 1992\[[@CR71]\]0-171978-1988NoYesWithin 2 weeks of diagnosisYesNANAPediatricians and endocrinologists reportsHospital registersNA93.3United States of America: Pennsylvania (Allegheny)Libman I. M., 1998^†^\[[@CR72]\]0-191990-1994NoYesFrom diagnosisYesNANAMedical reportsGeneral practitioners and diabetes nurses reportsNA97.7United States of America: Rhode IslandFishbein H. A., 1982^†^\[[@CR73]\]0-291979-1980NoYesNone declaredNANANAMedical reportsInsulin prescription registersNANAUnited States of America: five areas ^§^**Bell R., 2009** ^**†**^\[[@CR74]\]0-192002-2005**Yes**YesFrom diagnosisYesNANAMedical reportsOther health care registersThe SEARCH StudyNAUnited States of America: WisconsinAllen C., 1986^†^\[[@CR75]\]0-291970-1979NoYesFrom diagnosisYesNANAHospital dischargesPediatricians and endocrinologist reportsNA90.0United States of America: The United States NavyGorham C., 1993\[[@CR76]\]17-341974-1988NoNA\*None declaredYesNANAHospital dischargesNANANA**Western Pacific Region, HIGH**Australia: New South WalesTran F., 2014^†^\[[@CR77]\]10-182001-2008NoYesNAYesNAYesEndocrine group diabetes registerNational diabetes registerNA96.0Australia: Sydney (Southern Metropolitan Health Region)Sutton L., 1989^†^\[[@CR78]\]0-191984-1987NoYesFrom diagnosisYesNANAMedical reports from general practioners and pediatriciansSchools in the areaSyringe registerNAJapan: OsakaSasaki A., 1992^†^\[[@CR79]\]0-181978-1988NoYesNone declaredYesYesNAMedical benefits systemNANANANew Zealand: CanterburyScott, R. S., 1991^†^\[[@CR80]\]0- ≥ 801981-1986NoYesWithin 1 year of diagnosisYesNAYesCommunity-based surveys administrated in pharmacies where diabetic patients acquired their insulin suppliesHospital admission and discharge registers and diabetologistNA95.0**Other Regions currently non WHO**Taiwan: NW**Lin W.-H., 2013** ^**†**^\[[@CR81]\]0- ≥ 601999-2010**Yes**YesNone declaredYesYesNANational Health Insure register and Illness certificatesRandom sample of a database used to reimbursementsNA98.3US Virgin Islands: NWWashington R. E., 2013^†^\[[@CR82]\]0-192001-2010NoYesFrom diagnosisYesYesYesMedical reportsMedical providersNA98.7WHO Member States are divided into high-income (HIGH) or low- and middle-income (LMIC) states \[[@CR30]\]. AA: autoantibodies, NW: Nation-wide study, NA: Unavailable data. (a) When there were diagnostic doubts, (b) Only for patients aged over 40 years at onset, (c) Not performed in all cases; the author of this study was contacted to confirm the proportion of these cases, but by the time of submission of this paper no answer was available. T1D: Type 1 Diabetes. Highlighted: reports of the systematic review using the autoantibodies/C-peptide as diagnosis criteria. (^†^) Studies used in the statistical analyses. (\*) Data were not available but researchers assumed that patients have had T1D based on their average of age. (^§^) Ohio (8 counties), Washington State (5 counties), South Carolina, Colorado, California.

A *primary* source of information was reported in 99% (70 of 71) of the studies: among these reported sources, 60% (42 of 70) were from medical/hospital records, 36% (25 of 70) from national or regional registers, and 4% (3 of 70) from other sources, such as community-based surveys; a *secondary* source of information was reported in 90% (64 of 71) of the studies: among these reported sources, 58% (37 of 64) were from medical/hospital records, 16% (10 of 64) from associations of patients, 14% (9 of 64) from drug or supplies prescription registers, 8% (5 of 64) from national or regional registers, and 5% (3 of 64) from death certificates and schools registers; finally, a *tertiary* source of information was reported in 21% (15 of 71) of the studies: among these reported sources, 27% (4 of 15) were from national or regional registers, 27% (4 of 15) from associations of patients, 20% (3 of 15) from death certificates, 20% (3 of 15) from drug or supplies prescription registers, and 7% (1 of 15) from medical registers; see details in Table [1](#Tab1){ref-type="table"}. Percentage of ascertainment (completeness) between sources of information was evaluated in 53 of 71 (75%) studies. The mean percentage of ascertainment of these 53 studies was 94% (Table [1](#Tab1){ref-type="table"}).

In the group of young adults (15--19), the lowest incidence of T1D was reported in Mauritius, (1.1/100.000 persons/year) \[[@CR13]\], and the highest in Estonia (39.9/100.000 persons/year) \[[@CR19]\]. In the 70--79 year age group, the lowest incidence was reported in Navarra, Spain (0.8/100.000 persons/year) \[[@CR57]\] and the highest in Kronoberg, Sweden (55/100.000 persons /year) \[[@CR63]\]. The details of all retrieved incidence by study and age classes are in Additional file [4](#MOESM4){ref-type="media"}: Table S1.

Diagnostic criteria used to define T1D in adults reported in 71 epidemiological studies {#Sec10}
---------------------------------------------------------------------------------------

Autoantibodies against beta-cell antigens or the C-peptide were included in the T1D diagnostic criteria in 14 studies \[[@CR15],[@CR30]-[@CR32],[@CR34],[@CR35],[@CR45],[@CR46],[@CR54],[@CR56],[@CR57],[@CR63],[@CR74],[@CR81]\], detection of ICAs was reported in 9 studies \[[@CR15],[@CR30]-[@CR32],[@CR34],[@CR45],[@CR46],[@CR54],[@CR63]\], IAA in 4 studies \[[@CR30]-[@CR32],[@CR54]\], IA2 in 5 studies \[[@CR30]-[@CR32],[@CR56],[@CR57]\], and GAD in 11 studies \[[@CR30]-[@CR32],[@CR35],[@CR45],[@CR46],[@CR56],[@CR57],[@CR63],[@CR74],[@CR81]\]. The C-peptide was measured in 7 studies. In one paper difference of auto-antibodies by age group (0--19) was explored but no significant differences were detected \[[@CR74]\]. The other reported diagnostic criteria for T1D were the need for insulin therapy (reported in 70 of 71 studies), clinical symptoms of diabetes (reported in 56 of 71 studies), low or normal body weight (14 of 71 studies), and ketosis or ketonuria (26 of 71 studies). The details are shown in Table [1](#Tab1){ref-type="table"}.

Comparison of adult and children T1D incidences {#Sec11}
-----------------------------------------------

The variations of incidence of T1D in adults with country and age were studied in each area for which we retrieved information on a geographically defined population. This concerned 35 countries.

### Variation of T1D incidence with age in adults {#Sec12}

In 23 out of 35 (66%) countries (55 of 71 studies), the incidence of T1D was higher in the age range of 0--14 compared with 15--19 years. When restricted to the 14 reports for which the criteria of diagnosis of T1D were auto-antibodies against beta-cells or C-peptide detection, the variation of adult incidence with age showed a consistent decrease after the age of 14 years (Figure [2](#Fig2){ref-type="fig"} and Additional file [4](#MOESM4){ref-type="media"}: Table S1).Figure 2**Age variation of incidence from childhood to adult age.** On this figure, the adult estimates of incidence were taken from the 14 reports of the systematic review using the autoantibodies/C-peptide as diagnostic criteria. Full lines correspond to articles from which both child as well as adult information could be retrieved. The dotted lines are those for which the child information was searched in the same country as in the adult paper, but was from a different paper (see Additional file [3](#MOESM3){ref-type="media"} for details on this literature search). The corresponding countries are shown as: BE1: Belgium (2007) \[[@CR30]\]; BE2: Belgium (2002) \[[@CR31]\]; BE3: Belgium (1997) \[[@CR32]\]; DK: Denmark \[[@CR34]\]; ES1: Spain, Catalonia \[[@CR54]\]; ES2: Spain, Navarra (2014) \[[@CR56]\]; ES3: Spain, Navarra (2013) \[[@CR57]\]; FI: Finland \[[@CR35]\]; IR: Iran (Islamic Republic of) \[[@CR15]\]; IT: Italy \[[@CR45],[@CR46]\]; SE: Sweden \[[@CR63]\], TW: Taiwan \[[@CR81]\]; US: United States of America \[[@CR74]\].

### Geographical correlation of adult and child T1D incidence {#Sec13}

A significant geographical correlation, as measured by the Spearman correlation coefficient, was found between adult T1D incidence and 0--14 incidence in the age classes 15--19 years, 20--24 years, 25--29 years, 30--34 years and overall in the entire 15--60 group (*r* = 0.75, *p*-value: 5.7 *×* 10^−10^). The correlation was not significant in the oldest class where sparse data were available, but the relation was similar (Figure [3](#Fig3){ref-type="fig"}).Figure 3**Geographical correlation of T1D incidence between individuals aged 0--14 years and adults.** Studies using autoantibodies/C-Peptide for T1D case definition are identified by Red diamonds. The corresponding countries are shown as: BE1: Belgium (2007) \[[@CR30]\]; BE2: Belgium (2002) \[[@CR31]\]; BE3: Belgium (1997) \[[@CR32]\]; DK: Denmark \[[@CR34]\]; ES1: Spain, Catalonia \[[@CR54]\]; ES2: Spain, Navarra (2014) \[[@CR56]\]; ES3: Spain, Navarra (2013) \[[@CR57]\]; FI: Finland \[[@CR35]\]; IR: Iran (Islamic Republic of) \[[@CR15]\]; IT: Italy \[[@CR45],[@CR46]\]; SE: Sweden \[[@CR63]\], TW: Taiwan \[[@CR81]\]; US: United States of America \[[@CR74]\]. Sp. Cor: Spearman correlation.

Comparison of male and female T1D adult incidences {#Sec14}
--------------------------------------------------

T1D incidence was larger in males aged 15 to 39 years than in females in 44 (81%) of the 54 studies reporting incidence by sex (Additional file [5](#MOESM5){ref-type="media"}: Table S2). The mean male-to-female ratio in our review was 1.47 (95% CI for mean 1.33-1.60, SD = 0.49, *n* = 54, *p =* \< 0.0001).

Discussion {#Sec15}
==========

A first result of this systematic review is the paucity of data available on adult incidence of T1D as compared to those concerning children. The 71 studies retrieved provided information on adult T1D in only 35 countries, 40% of the 88 countries with primary childhood T1D incidence information in the 6th IDF atlas \[[@CR1]\].

A second result is that only a small proportion (*n* = 14) of the 71 studies used detection of specific autoantibodies and/or dosage of C-peptide \[[@CR83]\] as diagnostic criteria of adult T1D.

A third result was that in a majority of the retrieved studies, adult T1D incidence was greater in men than in women, which contrasts with incidence of T1D in children where sex ratio is around one \[[@CR2],[@CR84]\]. Using comparative data, Karvonen et al. also described a male excess among young adults in the 15--39 years of age \[[@CR85]\]. Sex differences in exposure to possible environmental triggers of T1D, in hormonal/genetic susceptibility, in lifestyle have been proposed as possible explanations for this difference \[[@CR62]\].

A last striking observation of the current analysis is the strong geographical correlation of the incidences in adults and children. This correlation may be explained by the fact that adults with T1D share the gene alleles known to be associated to incidence of T1D in children, \[[@CR86],[@CR87]\], and/or some predisposing environmental causes \[[@CR4]\]. For example, in a previous study on incidence of T1D in children, a significant positive correlation was detected between the percentage of urban population and the incidence of T1D in children (*r* = 0.41 *p-*value: \< 0.0001) \[[@CR4]\]; in this review a significantly higher urban proportion of T1D incidence among adults was found in 4 of the 7 studies reporting differences between rural *vs* urban areas \[[@CR15],[@CR21],[@CR42],[@CR75]\].

There was an overall decrease of incidence with age in adults and young adults after the age of 14. A second peak of T1D around the age of 50, as described by Krolewski et al. \[[@CR88]\], was only reported in 7% (4 of 58) of the studies \[[@CR18],[@CR63],[@CR80],[@CR89]\].

The paucity of data made it impossible to document an increase in adult T1D incidence that would parallel the dramatic increase observed in children \[[@CR2],[@CR3],[@CR90]\]. Indeed, successive studies in the same region over different periods reporting incidence in people aged \>30 years of age were only found for Belgium \[[@CR30]-[@CR32]\], Lithuania \[[@CR20]-[@CR22]\] and Sweden \[[@CR58]-[@CR62]\]. Similarly, this review did not dispose of sufficient data to document differences in the clinical presentation of T1D of adults and children as suggested elsewhere \[[@CR32],[@CR40]\]; indeed only two of the 71 studies describe differences in clinical presentation of T1D between adults and children \[[@CR89],[@CR91]\].

Improving the quantity and quality of information on adult T1D is not only useful to better understand the epidemiology and natural history of T1D, but can have practical consequences, as delay of T1D diagnosis may mean retardation in insulin treatment, lost opportunities for potential prevention of acute and chronic complications, and even death \[[@CR92]\]: in Croatia \[[@CR18]\], 14% of the incident cases were identified solely through death certificates, and high mortality was found in the newly-diagnosed T1D aged over 50.

Conclusions {#Sec16}
===========

Overall, the results of this systematic review should encourage the launching of epidemiological studies of adult T1D with specific diagnostic criteria.

Availability of supporting data {#Sec17}
-------------------------------

All the supporting data are included as additional files.

Additional files {#Sec18}
================

Additional file 1:**Search equation used for the bibliographic analysis.**Additional file 2:**PRISMA checklist.**Additional file 3:**List of selected papers reporting incidence of T1D in 0--14 year-olds in 9 countries.**Additional file 4: Table S1.Geographic repartition, and reported adult T1D incidences found in the systematic review. Incidence was per 100.000 persons per year. T1D: Type 1 Diabetes. NW: Nation-wide study. HIGH, LMIC: High, Low-Medium Income Level. Highlighted: reports of the systematic review using the autoantibodies/C-peptide as diagnosis criteria. (a) 0--9 years of age, (b) 10--19 years of age, (c) 10--18 years of age, (d) 15--17 years of age, (e) 15--18 years of age, (−−-): unavailable data. (\*): Data was retrieved from a different study; for details see Additional file [3](#MOESM3){ref-type="media"}. (†) Studies used in the geographical correlation analyses. (‡) Special population. (§) The five areas were Ohio (8 counties), Washington State (5 counties), South Carolina, Colorado and California; the table presents the mean incidence calculated, retrieved from 5 populations: African American, Asian Pacific Islander, Navajo, Hispanic and non-Hispanic young.Additional file 5: Table S2.T1D incidences by sex in young adults and adults found in the Systematic Review. Male-to-Female ratios \>1 are highlighted. Ref: Reference. First author and publication year in reports of the systematic review using the autoantibodies/C-peptide as diagnosis criteria are highlighted. Inc: incidence per 100.000 persons per year. NW: Nation-wide study. HIGH, LMIC: High, Low-Medium Income Level. (†) Studies used for analyses. (§) The five areas were Ohio (8 counties), Washington State (5 counties), South Carolina, Colorado and California; the table presents the mean incidence calculated retrieved from 5 populations: African American, Asian Pacific Islander, Navajo, Hispanic and non-Hispanic young. Incidence was calculated as the mean of retrieved information: (a) in Jews and other non-Arabs and Arabs; (b) in White and Black populations; (c) in Non-Hispanic Whites and Hispanic Whites. (d) Study giving the total incidence by sex, not by age classes.
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